Enterprise Value
3.128B
Cash
45.33M
Avg Qtr Burn
N/A
Short % of Float
3.63%
Insider Ownership
2.59%
Institutional Own.
79.05%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nabi-HB® Details Hepatitis B | Approved Quarterly sales | |
ASCENIV™ Details Immunodeficiency, Autoimmune disease, Primary humoral immunodeficiency | Approved Quarterly sales | |
BIVIGAM® Details Autoimmune disease, Immunodeficiency, Primary humoral immunodeficiency | Approved Quarterly sales |